[go: up one dir, main page]

TW200734339A - Forms of dolasetron mesylate and processes for their preparation - Google Patents

Forms of dolasetron mesylate and processes for their preparation

Info

Publication number
TW200734339A
TW200734339A TW096100622A TW96100622A TW200734339A TW 200734339 A TW200734339 A TW 200734339A TW 096100622 A TW096100622 A TW 096100622A TW 96100622 A TW96100622 A TW 96100622A TW 200734339 A TW200734339 A TW 200734339A
Authority
TW
Taiwan
Prior art keywords
processes
preparation
forms
dolasetron mesylate
dolasetron
Prior art date
Application number
TW096100622A
Other languages
English (en)
Inventor
Janos Hajko
Erika Magyar Molnarne
Tivadar Tamas
Csaba Peto
Adrienne Kovacsne-Mezei
Csaba Szabo
Original Assignee
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag filed Critical Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag
Publication of TW200734339A publication Critical patent/TW200734339A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/38Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
TW096100622A 2006-01-05 2007-01-05 Forms of dolasetron mesylate and processes for their preparation TW200734339A (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US75669006P 2006-01-05 2006-01-05
US76368306P 2006-01-30 2006-01-30
US78424806P 2006-03-20 2006-03-20
US80088406P 2006-05-15 2006-05-15
US80284206P 2006-05-22 2006-05-22
US81519906P 2006-06-19 2006-06-19
US81893406P 2006-07-05 2006-07-05
US83351506P 2006-07-24 2006-07-24
US83643206P 2006-08-07 2006-08-07
US83875806P 2006-08-17 2006-08-17
US85288706P 2006-10-18 2006-10-18
US86135406P 2006-11-27 2006-11-27

Publications (1)

Publication Number Publication Date
TW200734339A true TW200734339A (en) 2007-09-16

Family

ID=37913602

Family Applications (2)

Application Number Title Priority Date Filing Date
TW096100622A TW200734339A (en) 2006-01-05 2007-01-05 Forms of dolasetron mesylate and processes for their preparation
TW096100606A TW200734326A (en) 2006-01-05 2007-01-05 Crystalline forms of dolasetron base and processes for preparation thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW096100606A TW200734326A (en) 2006-01-05 2007-01-05 Crystalline forms of dolasetron base and processes for preparation thereof

Country Status (5)

Country Link
US (4) US7608714B2 (zh)
EP (4) EP1861397A2 (zh)
IL (4) IL190723A0 (zh)
TW (2) TW200734339A (zh)
WO (4) WO2007081907A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030207A1 (en) * 2007-07-20 2009-01-29 Janos Hajko Polymorphs of Dolasetron base and process for preparation thereof
WO2009014679A1 (en) * 2007-07-20 2009-01-29 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Dolasetron trifluoroacetate, polymorphs of dolasetron trifluoroacetate and process for preparation thereof
ES2389261T3 (es) * 2007-11-13 2012-10-24 Inke, S.A. Compuestos intermedios útiles para preparar dolasetrón
US9096805B2 (en) * 2008-06-04 2015-08-04 Nalco Company Anhydride demulsifier formulations for resolving emulsions of water and oil
US8969262B2 (en) * 2008-06-04 2015-03-03 Nalco Company Utilization of an anhydride as a demulsifier and a solvent for demulsifier formulations
CN102180878B (zh) * 2010-07-02 2013-06-26 成都新恒创药业有限公司 一种多拉司琼异构体或其盐及其制备方法和其应用
CN103360392A (zh) * 2013-06-21 2013-10-23 辽宁海思科制药有限公司 一种甲磺酸多拉司琼化合物
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
TW201825470A (zh) * 2016-11-24 2018-07-16 日商帝人製藥股份有限公司 環氧化合物的製造方法
CN109503580A (zh) * 2019-01-15 2019-03-22 南京恩泰医药科技有限公司 一种甲磺酸多拉司琼晶型及制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
ZA878096B (en) 1986-11-03 1988-04-26 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds
EP0329905A1 (en) * 1988-02-23 1989-08-30 Merrell Dow Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
EP0330788A1 (en) * 1988-03-01 1989-09-06 Merrell Dow Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia
ZA893008B (en) 1988-04-29 1989-12-27 Merrell Dow Pharma Process for preparing indole-3-carboxylic acid esters of transhexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines
US5665890A (en) * 1995-03-14 1997-09-09 President And Fellows Of Harvard College Stereoselective ring opening reactions
CN100390172C (zh) * 2004-09-10 2008-05-28 成都欣捷高新技术开发有限公司 一种甲磺酸多拉司琼晶型及其制备方法
WO2006056081A1 (de) * 2004-11-25 2006-06-01 Cilag Ltd. Verfahren zur herstellung von estern von hexahydro-8-hydroxy-2,6-methano-2h-chinolizin-3(4h)-on
ES2314927T3 (es) * 2005-07-06 2009-03-16 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo, sus intermedios de sintesis y procedimientos para la obtencion de los mismos.
US20080275241A1 (en) 2005-12-23 2008-11-06 Tarur Venkatasubramanian Radha Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof

Also Published As

Publication number Publication date
US7608714B2 (en) 2009-10-27
IL190724A0 (en) 2008-11-03
WO2007081889A9 (en) 2007-09-20
EP1968978A2 (en) 2008-09-17
US20070203219A1 (en) 2007-08-30
IL190723A0 (en) 2008-11-03
US20070203176A1 (en) 2007-08-30
US20070203175A1 (en) 2007-08-30
US20070203177A1 (en) 2007-08-30
WO2007081890A8 (en) 2008-08-14
WO2007081889A8 (en) 2008-08-21
EP1861397A2 (en) 2007-12-05
EP1968588A2 (en) 2008-09-17
TW200734326A (en) 2007-09-16
IL190725A0 (en) 2008-11-03
WO2007081907A3 (en) 2008-01-17
WO2007081889A3 (en) 2007-08-23
EP1874767A2 (en) 2008-01-09
WO2007081889A2 (en) 2007-07-19
IL190914A0 (en) 2008-11-03
WO2007081890A2 (en) 2007-07-19
WO2007081909A2 (en) 2007-07-19
WO2007081907A2 (en) 2007-07-19
WO2007081890A3 (en) 2007-09-27
WO2007081909A3 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
WO2011072099A3 (en) Compositions and methods comprising protease variants
PH12013502230A1 (en) Multispecific antibodies
WO2007127834A3 (en) Compositions and methods of preparation thereof
WO2009067674A3 (en) Polymorphs of sunitinib base and processes for preparation thereof
MX2010004374A (es) Armazones proteinicos.
TW200732349A (en) Anti-OX40L antibodies and methods using same
IL188330A0 (en) Processes for the preparation of
WO2008127290A3 (en) Alginate and alginate lyase compositions and methods of use
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
WO2011047087A3 (en) Protein detection via nanoreporters
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2011130222A3 (en) Compositions and methods comprising variant proteases
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
IL176142A (en) Processes for preparing montelukast sodium
WO2008027600A3 (en) Imatinib compositions
WO2008075205A3 (en) Improved process for the preparation of voriconazole
TW200734339A (en) Forms of dolasetron mesylate and processes for their preparation
WO2010037095A3 (en) Agents and methods for the treatment of cancer